

### REMARKS

Upon entry of the amendments submitted herewith, claims 36 to 39, 41 to 47, and 95 to 108 are currently pending in the instant application. Claims 1 to 35, 40, and 48 to 94 are canceled without prejudice. Claims 95 to 108 are newly introduced. No new matter is added by way of these amendments and newly introduced claims.

Support for newly introduced claims 95 to 108 is found throughout the specification as filed, for example, at page 7, lines 26 to 28; page 11, lines 7 to 11; page 37, lines 16 to 18; and in the claims as originally filed.

The Examiner has restricted claims 1 to 94 into seven groups. Applicants elect Group IV, containing claims 36 to 48, with traverse. In accordance with the restriction requirement and solely in an effort to advance prosecution, Applicants have canceled claims 1 to 35, 40, and 48 to 94. However, Applicants reserve the right to pursue the canceled subject matter in one or more divisional applications.

Newly introduced claims 95 to 108 depend from the elected claims of Group IV. Accordingly, Applicants request that claims 95 to 108 be examined with claims 36 to 48.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. § 121. The Examiner is invited to contact the undersigned at the telephone number provided below if there are any questions regarding Applicants' claimed invention.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 50-0252.

Respectfully submitted,

Dated: September 5, 2006

By: Frances P. Putkey  
Frances Putkey, Ph.D.  
Registration No. 57,257

Isis Pharmaceuticals, Inc  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
(760) 603-2710 – Phone  
(760) 603-3820 – Facsimile